Noble Financial Restated “Buy” Rating For Endeavour Silver (EXK); SANTEN PHARMACEUTICA (SNPHF) Sellers Increased By 3.02% Their Shorts

SANTEN PHARMACEUTICA (OTCMKTS:SNPHF) had an increase of 3.02% in short interest. SNPHF’s SI was 2.22 million shares in January as released by FINRA. Its up 3.02% from 2.15M shares previously. With 300 avg volume, 7388 days are for SANTEN PHARMACEUTICA (OTCMKTS:SNPHF)’s short sellers to cover SNPHF’s short positions. It closed at $15.25 lastly. It is down 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 8 analysts covering Endeavour Silver Corp (NYSE:EXK), 3 have Buy rating, 1 Sell and 4 Hold. Therefore 38% are positive. Endeavour Silver Corp has $6.5000 highest and $2.30 lowest target. $4.30’s average target is 63.50% above currents $2.63 stock price. Endeavour Silver Corp had 27 analyst reports since August 24, 2015 according to SRatingsIntel. The firm has “Sell” rating given on Monday, August 24 by Zacks. The stock of Endeavour Silver Corp. (NYSE:EXK) earned “Buy” rating by Noble Financial on Friday, March 31. The rating was maintained by H.C. Wainwright on Friday, November 3 with “Buy”. The stock of Endeavour Silver Corp. (NYSE:EXK) earned “Market Perform” rating by BMO Capital Markets on Friday, November 17. Noble Financial maintained Endeavour Silver Corp. (NYSE:EXK) on Friday, August 4 with “Buy” rating. The company was downgraded on Monday, January 9 by Canaccord Genuity. As per Tuesday, February 23, the company rating was downgraded by IBC. The firm has “Buy” rating by Noble Financial given on Friday, February 17. H.C. Wainwright maintained it with “Buy” rating and $6.5000 target in Friday, July 14 report. Noble Financial maintained Endeavour Silver Corp. (NYSE:EXK) on Wednesday, October 11 with “Buy” rating.

Santen Pharmaceutical Co., Ltd., together with its subsidiaries, researches and develops, produces, and markets prescription ophthalmic pharmaceutical products for the protection and enhancement of eyesight and health primarily in Japan. The company has market cap of $6.64 billion. It offers prescription pharmaceutical products for corneal and conjunctival epithelial disorders, glaucoma and ocular hypertension, anti-rheumatics, retinal and uveal disorders, and allergy; over-the-counter pharmaceutical products; and medical devices, such as foldable intraocular lenses. It has a 27.38 P/E ratio. The firm also engages in the cleaning of anti-dust and sterilized clothing; and sale of supplements.

Endeavour Silver Corp., a mid-tier precious metals mining company, engages in evaluation, acquisition, exploration, development, extraction, processing, refining, and reclamation of silver mining properties in Mexico and Chile. The company has market cap of $328.62 million. The firm also explores for gold deposits. It has a 526 P/E ratio. It holds interest in the Guanacev?? mine in the Durango state; and the Bola??itos and El Cubo mines in the Guanajuato state of Mexico.

The stock increased 5.20% or $0.13 during the last trading session, reaching $2.63. About 1.61 million shares traded or 7.54% up from the average. Endeavour Silver Corp. (NYSE:EXK) has declined 7.14% since January 13, 2017 and is downtrending. It has underperformed by 23.84% the S&P500.